冠昊生物收盘上涨5.38%，滚动市盈率154.16倍，总市值40.54亿元

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Guanhao Biological, which has a closing price of 15.29 yuan, a 5.38% increase, and a rolling PE ratio of 154.16 times, with a total market value of 4.054 billion yuan [1] - Guanhao Biological operates in the regenerative medicine materials and medical implant devices sector, with key products including biological dura (spinal) membrane patches and sterile biological wound dressings [1] - As of the third quarter of 2025, Guanhao Biological reported a revenue of 293 million yuan, a year-on-year increase of 5.52%, while net profit was 26.7185 million yuan, a decrease of 4.02%, with a gross profit margin of 77.69% [1] Group 2 - In terms of industry comparison, the average PE ratio for the medical device sector is 52.19 times, with a median of 40.14 times, positioning Guanhao Biological at the 110th rank within the industry [1] - The company has six institutional investors holding a total of 75.8339 million shares, with a combined market value of 1.165 billion yuan [1] - The static PE ratio for Guanhao Biological is reported at 147.87 times, with a price-to-book ratio of 7.09 [2]